Intracellular immunoglobulin A ( icIgA ) in protective immunity and vaccines
Scandinavian Journal of Immunology · 2023
DOI: 10.1111/sji.13253 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Scandinavian Journal of Immunology, 2023. Verfasst von Tuck-Weng Kok und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of Adelaide, Faculty of Health & Medical Sciences and School of Biological Sciences, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: COVID-19, Vaccines, Receptors, Polymeric Immunoglobulin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Virus neutralization at respiratory mucosal surfaces is important in the prevention of infection. Mucosal immunity is mediated mainly by extracellular secretory immunoglobulin A (sIgA) and its role has been well studied. However, the protective role of intracellular specific IgA (icIgA) is less well defined. Initially, in vitro studies using epithelial cell lines with surface expressed polymeric immunoglobulin receptor (pIgR) in transwell culture chambers have shown that icIgA can neutralize influenza, parainfluenza, HIV, rotavirus and measles viruses. This effect appears to involve an interaction between polymeric immunoglobulin A (pIgA) and viral particles within an intracellular compartment, since IgA is transported across the polarized cell. Co‐localization of specific icIgA with influenza virus in patients' (virus culture positive) respiratory epithelial cells using well‐characterized antisera was initially reported in 2018. This review provides a summary of in vitro studies with icIgA on colocalization and neutralization of the above five viruses. Two other highly significant respiratory infectious agents with severe global impacts viz. SARS‐2 virus (CoViD pandemic) and the intracellular bacterium— Mycobacterium tuberculosis —are discussed. Further studies will provide more detailed understanding of the mechanisms and kinetics of icIgA neutralization in relation to viral entry and early replication steps with a specific focus on mucosal infections. This will inform the design of more effective vaccines against infectious agents transmitted via the mucosal route.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Adelaide, Faculty of Health & Medical Sciences and School of Biological Sciences, Adelaide, South Australia, Australia.
- University of Sydney, Tuberculosis Research Program, Centenary Institute, Camperdown, New South Wales, Australia.
- University of South Australia, Clinical and Health Sciences and Centre for Cancer Biology, Adelaide, South Australia, Australia.
ORCID-Profile: Tuck-Weng Kok, Angelo A Izzo, Maurizio Costabile
Zitieren
APA
Kok, T. W., Izzo, A. A., & Costabile, M. (2023). Intracellular immunoglobulin A ( icIgA ) in protective immunity and vaccines. Scandinavian Journal of Immunology. https://doi.org/10.1111/sji.13253
Vancouver
Kok TW, Izzo AA, Costabile M. Intracellular immunoglobulin A ( icIgA ) in protective immunity and vaccines. Scandinavian Journal of Immunology. 2023. doi:10.1111/sji.13253
BibTeX
@article{Kok2023,
author = {Kok, Tuck-Weng and Izzo, Angelo A and Costabile, Maurizio},
title = {Intracellular immunoglobulin A ( icIgA ) in protective immunity and vaccines},
journal = {Scandinavian Journal of Immunology},
year = {2023},
doi = {10.1111/sji.13253}
}
EUVIMED